DUBAI, United Arab Emirates, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Vector Pharma FZCO announced today the signing of an exclusive distribution agreement with R-PHARM US of Princeton, NJ . “I am honored to announce this regional agreement with R-Pharm US,” commented Vector Pharma FZCO Managing Director Samer Semaan. “Ixempra is an important therapy for patients with advanced breast cancer; the women across MENA will benefit from access to this therapy. Vector Pharma is also a proud founding member of the World Orphan Drug Alliance (WODA) offering its services together with like-minded sister companies in Switzerland, CEE, Russia, and Latin America. R-PHARM’s portfolio includes IXEMPRA, a chemotherapy agent approved for metastatic breast cancer, and a pipeline that includes molecules being developed for immunology and oncology indications.

Source: The North Africa Journal December 22, 2021 14:47 UTC